Abstract

Diabetic cardiomyopathy (DCM) is a chronic complication of diabetes mellitus, characterized by abnormalities of myocardial structure and function. Researches on the models of type 1 and type 2 diabetes mellitus as well as the application of genetic engineering technology help in understanding the molecular mechanism of DCM. DCM has multiple hallmarks, including hyperglycemia, insulin resistance, increased free radical production, lipid peroxidation, mitochondrial dysfunction, endothelial dysfunction, and cell death. Essentially, cell death is considered to be the terminal pathway of cardiomyocytes during DCM. Morphologically, cell death can be classified into four different forms: apoptosis, autophagy, necrosis, and entosis. Apoptosis, as type I cell death, is the fastest form of cell death and mainly occurs depending on the caspase proteolytic cascade. Autophagy, as type II cell death, is a degradation process to remove damaged proteins, dysfunctional organelles and commences by the formation of autophagosome. Necrosis is type III cell death, which contains a great diversity of cell death processes, such as necroptosis and pyroptosis. Entosis is type IV cell death, displaying “cell-in-cell” cytological features and requires the engulfing cells to execute. There are also some other types of cell death such as ferroptosis, parthanatos, netotic cell death, lysosomal dependent cell death, alkaliptosis or oxeiptosis, which are possibly involved in DCM. Drugs or compounds targeting the signals involved in cell death have been used in clinics or experiments to treat DCM. This review briefly summarizes the mechanisms and implications of cell death in DCM, which is beneficial to improve the understanding of cell death in DCM and may propose novel and ideal strategies in future.

Highlights

  • Diabetic cardiomyopathy (DCM) is manifested as specific abnormalities of myocardial structure and function in diabetic patients without hypertension or coronary artery disease in clinic

  • DCM is often imitated in rat embryonic heart derived H9C2 cells, neonatal cardiomyocytes or cardiac fibroblasts with high glucose (HG) or advance glycation end product (AGE) stimulation (Sun et al, 2019a; Tang et al, 2019b; Wang et al, 2019a)

  • Our recent research revealed that inhibitor 1 of protein phosphatase 1 (I1PP1) over-expression alleviated CaMKIId alternative splicing disorder, suppressed Reactive oxygen species (ROS) overproduction, inhibited Calmodulindependent protein kinase II (CaMKII) oxidation, suppressed necroptosis, and alleviated high glucose-induced cardiomyocyte injury (Sun et al, 2019a)

Read more

Summary

Introduction

Diabetic cardiomyopathy (DCM) is manifested as specific abnormalities of myocardial structure and function in diabetic patients without hypertension or coronary artery disease in clinic. Induced-H9C2 cell apoptosis by reducing Cyto C release and inhibiting caspase activity. APS provided cardioprotective effects on DCM by inhibiting cardiomyocytes apoptosis via suppressing protein kinase RNA-like ER kinase (PERK) and activating transcription factor 6 (ATF6)-related pathway of ER stress (Sun et al, 2019c).

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call